Redefining Treatment Success in Patients With Parkinson’s Disease
CONCLUSIONS
The global burden of PD will continue to increase over the next 25 years, accompanied by a substantial rise in associated healthcare utilization and costs. Challenges in diagnosing PD, specifically in recognizing the subtle nonmotor symptoms of the disease, underscore the need for enhanced awareness of techniques for diagnosing and monitoring the progression of PD. Symptom-based criteria provide effective scales for monitoring treatment of PD, but patient HRQOL should be included in the definition of treatment success. Emerging disease-modifying therapies may provide improved long-term patient outcomes and increased treatment success for patients with PD. Until clinical research identifies disease-specific biomarkers to allow the development of neuroprotective therapies, effective management of the motor and nonmotor symptoms of PD through an individualized, patient-focused perspective is needed to minimize disability, improve HRQOL, and ultimately achieve treatment success.
REFERENCES
1. Fahn S, Sulzer D. Neurodegeneration and neuroprotection in Parkinson disease. NeuroRx. 2004;1(1):139-154. 2. Jankovic J. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008;79(4):368-376. 3. Parkinson J. An essay on the shaking palsy. 1817. J Neuropsychiatry Clin Neurosci. 2002;14(2):223-236. 4. Berardelli A, Rothwell JC, Thompson PD, Hallett M. Pathophysiology of bradykinesia in Parkinson's disease. Brain. 2001;124(pt 11):2131-2146. 5. Riley D, Lang AE, Blair RD, Birnbaum A, Reid B. Frozen shoulder and other shoulder disturbances in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1989;52(1):63-66. 6. Bhidayasiri R. Differential diagnosis of common tremor syndromes. Postgrad Med J. 2005;81(962):756-762. 7. Williams DR, Watt HC, Lees AJ. Predictors of falls and fractures in bradykinetic rigid syndromes: a retrospective study. J Neurol Neurosurg Psychiatry. 2006;77(4):468-473. 8. Thanvi BR, Munshi SK, Vijaykumar N, Lo TC. Neuropsychiatric non-motor aspects of Parkinson's disease. Postgrad Med J. 2003;79(936):561-565. 9. Weintraub D, Comella CL, Horn S. Parkinson's disease—part 1: pathophysiology, symptoms, burden, diagnosis, and assessment. Am J Manag Care. 2008;14(2 suppl):S40-S48. 10. Dorsey ER, Constantinescu R, Thompson JP, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 2007;68(5):384-386. 11. Weintraub D, Comella CL, Horn S. Parkinson's disease—part 2: treatment of motor symptoms. Am J Manag Care. 2008;14(2 suppl):S49-S58. 12. Jankovic J. An update on the treatment of Parkinson's disease. Mt Sinai J Med. 2006;73(4):682-689. 13. Fahn S, Oakes D, Shoulson I, et al, and the Parkinson Study Group. Levodopa and the progression of Parkinson's disease. N Engl J Med. 2004;351(24):2498-2508. 14. Marek K, Jennings D, Seibyl J. Do dopamine agonists or levodopa modify Parkinson's disease progression? Eur J Neurol. 2002;9(suppl 3):15-22. 15. Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology. 2001;56(11 suppl 5):S1-S88. 16. Pahwa R, Factor SA, Lyons KE, et al. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66(7):983-995. 17. Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinson's disease? J Neurol Neurosurg Psychiatry. 2000;69(3):308-312. 18. Karlsen KH, Tandberg E, Arsland D, Larsen JP. Health related quality of life in Parkinson's disease: a prospective longitudinal study. J Neurol Neurosurg Psychiatry. 2000;69(5):584-589. 19. Shulman LM, Taback RL, Bean J, Weiner WJ. Comorbidity of the nonmotor symptoms of Parkinson's disease. Mov Disord. 2001;16(3):507-510. 20. Jeffrey S. Psychiatric symptoms have greater impact in early vs late PD. Medscape Medical News, October 10, 2007. www.medscape.com/viewarticle/564104. Accessed June 20, 2008. 21. Schapira AHV, Obeso J. Timing of treatment initiation in Parkinson's disease: a need for reappraisal? Ann Neurol. 2006;59(3):559-562. 22. Goetz CG, Fahn S, Martinez-Martin P, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): process, format, and clinimetric testing plan. Mov Disord. 2007;22(1):41-47. 23. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;17(5):427-442. 24. Ramaker C, Marinus J, Stiggelbout AM, Van Hilten BJ. Systematic evaluation of rating scales for impairment and disability in Parkinson's disease. Mov Disord. 2002;17(5):867-876. 25. Movement Disorder Society Task Force on Rating Scales for Parkinson’s Disease. The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations. Mov Disord. 2003;18(7):738-750. 26. Hoehn and Yahr staging of Parkinson's disease, Unified Parkinson disease rating scale (UPDRS), and Schwab and England activities of daily living. National Parkinson Foundation. http://www.parkinson.org/NETCOMMUNITY/Page.aspx?pid=367&srcid=202. Accessed July 1, 2008. 27. Waters CH. Diagnosis. In: Diagnosis and management of Parkinson's disease. 5th ed. Caddo, OK: Professional Communications, Inc; 2006:63-102. 28. Chaudhuri KR, Healy DG, Schapira AH, and the National Institute for Clinical Excellence. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol. 2006;5(3):235-245. 29. Miyasaki JM, Shannon K, Voon V, et al, and the Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66(7):996-1002. 30. Visser M, Verbaan D, van Rooden SM, Stiggelbout AM, Marinus J, van Hilten JJ. Assessment of psychiatric complications in Parkinson's disease: the SCOPA-PC. Mov Disord. 2007;22(15):2221-2228. 31. Martinez-Martin P, Schapira AH, Stocchi F, et al. Prevalence of nonmotor symptoms in Parkinson's disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients. Mov Disord. 2007;22(11):1623-1629. 32. Marinus J, Ramaker C, van Hilten JJ, Stiggelbout AM. Health related quality of life in Parkinson's disease: a systematic review of disease specific instruments. J Neurol Neurosurg Psychiatry. 2002;72(2):241-248. 33. Calne SM, Mak E, Hall J, et al. Validating a quality-of-life scale in caregivers of patients with Parkinson's disease: Parkinson's Impact Scale (PIMS). Adv Neurol. 2003;91:115-122. 34. de Boer AG, Wijker W, Speelman JD, de Haes JC. Quality of life in patients with Parkinson's disease: development of a questionnaire. J Neurol Neurosurg Psychiatry. 1996;61(1):70-74. 35. Jenkinson C, Fitzpatrick R, Peto V, Greenhall R, Hyman N. The Parkinson's Disease Questionnaire (PDQ-39): development and validation of a Parkinson's disease summary index score. Age Ageing. 1997;26(5):353-357. 36. Peto V, Jenkinson C, Fitzpatrick R, Greenhall R. The development and validation of a short measure of functioning and well being for individuals with Parkinson's disease. Qual Life Res. 1995;4(3):241-248. 37. Welsh M, McDermott MP, Holloway RG, Plumb S, Pfeiffer R, Hubble J, and the Parkinson Study Group. Development and testing of the Parkinson's disease quality of life scale. Mov Disord. 2003;18(6):637-645. 38. Global Parkinson's Disease Survey (GPDS) Steering Committee. Factors impacting quality of life in Parkinson's disease: results from an international survey. Mov Disord. 2002;17(1):60-67. 39. Martinez-Martin P, Frades Payo B. Quality of life in Parkinson's disease: validation study of the PDQ-39 Spanish version. The Grupo Centro for Study of Movement Disorders. J Neurol. 1998;245(suppl 1):S34-S38. 40. Lecht S, Haroutiunian S, Hoffman A, Lazarovici P. Rasagiline—a novel MAO B inhibitor in Parkinson's disease therapy. Ther Clin Risk Manag. 2007;3(3):467-474. 41. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol. 2002;59(12):1937-1943. 42. Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol. 2004;61(4):561-566. 43. Olanow CW, Rascol O, for the ADAGIO Investigators. ADAGIO: a prospective, double-blind, delayed-start study to examine the potential disease-modifying effect of rasagiline in early Parkinson's disease (PD). Mov Dis. 2008;23(suppl 1):S194. 44. MAO-B inhibitors for the treatment of Parkinson's disease. Mov Disord. 2002;17(suppl 4):S38-S44. 45. Miyasaki JM, Martin W, Suchowersky O, Weiner WJ, Lang AE. Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2002;58(1):11-17. 46. NICE guidelines. June 2006. Available at http://www.nice.org.uk/nicemedia/pdf/word/CG035NICEguidelineword.doc. Accessed June 20, 2008
